Karen Long

Ms. Long is the Managing Director of KCK MedTech. KCK focuses capital investment on highly disruptive therapies within the medical device sector. Ms. Long has been with KCK since January 2018 when she joined as Executive-in-Residence. Within KCK, she serves as Board Director at Revelle Aesthetics, LungPacer Medical (transvascular diaphragm pacing), and Barologics (hypertension), as well as Chairman of the Board of Aerin Medical (ENT) and Sonex Health (orthopedics). In addition to KCK, Ms. Long sits on the Boards of Brius Technologies (orthodontics) and Natural Cycles (women’s consumer health).

Prior to KCK, Ms. Long was President and CEO of Nuelle, a women’s consumer health company incubated at ExploraMed. Nuelle was acquired in 2017. In early 2007, she joined Acclarent as Worldwide Vice President of Marketing and led Acclarent’s marketing efforts through rapid growth and ultimately through the acquisition by Johnson & Johnson. She remained with Johnson & Johnson until joining the ExploraMed incubator in 2012. Acclarent was also an early spinout from ExploraMed.

Ms. Long has spent over 20 years in medical devices and diagnostics developing and marketing novel and market-leading products focused on improving quality of life. She has held a series of key operating roles in consumer diagnostic companies, ChemTrak and Inverness Medical, and management positions at LifeScan, a Johnson & Johnson company, after the acquisition of Inverness Medical.

Ms. Long began her career as a Licensed Clinical Social Worker after receiving her undergraduate and graduate degrees from San Diego State University.